Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.45 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29762483 | 1.00 | MAPT (0.61) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL17204101 | 0.87 | MAPT (0.61) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL20267260 | 0.83 | MAPT (0.61) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL30068134 | 0.83 | MAPT (0.61) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL29434160 | 0.82 | MAPT (0.65) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL971891 | 0.82 | MAPT (0.65) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL29434159 | 0.82 | MAPT (0.65) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL14024999 | 0.82 | MAPT (0.56) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL29713891 | 0.81 | HRH4 (0.59) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL3634340 | 0.81 | HRH4 (0.59) | MAPTCYP1A2CYP2D6CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441736-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12312336-B2 | Inhibitors of RAF kinases | Pierre Fabre Médicament (FR) | 2025-05-27 | — | — | US | disclosed |
| EP-4472968-A1 | INHIBITORS OF RAF KINASES | PIERRE FABRE MEDICAMENT (FR) | 2024-12-11 | — | — | EP | disclosed |
| EP-3898592-B1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | AMGEN INC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2024-06-06 | — | — | US | disclosed |
| US-11814384-B2 | Inhibtors of Raf kinases | KINNATE BIOPHARMA INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2023-09-28 | — | — | US | disclosed |
| WO-2023150681-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-4048259-A1 | INHIBITORS OF RAF KINASES | Kinnate Biopharma Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114845711-A | Inhibitors of RAF kinase | 金耐特生物制药公司 | 2022-08-02 | — | — | CN | disclosed |
| EP-2150545-A1 | N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS | AstraZeneca AB (SE) | 2010-02-10 | — | — | EP | disclosed |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| WO-2009010789-A2 | PYRIMIDINE DERIVATIVES 934 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| US-20090023719-A1 | PYRIMIDINE DERIVATIVES 934 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023719-A1 | PYRIMIDINE DERIVATIVES 934 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023719-A1 | PYRIMIDINE DERIVATIVES 934 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2009010789-A2 | PYRIMIDINE DERIVATIVES 934 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008132505-A1 | N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132505-A1 | N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182467-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | MAPT 2859/4885CYP1A2 4302/4885CYP2D6 4339/4885 |
| US-12441736-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | MAPT 299/4885CYP1A2 2959/4885CYP2D6 4229/4885 |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | EPHB4, EPHB6, EPHB1 | MAPT 3461/4885CYP1A2 1950/4885CYP2D6 509/4885 |
| US-20090023719-A1 | PYRIMIDINE DERIVATIVES 934 | EPHB4, EPHA2, EPHB1 | MAPT 4133/4885CYP1A2 346/4885CYP2D6 271/4885 |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | MAPT 2859/4885CYP1A2 4302/4885CYP2D6 4339/4885 |
| US-12312336-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | MAPT 2859/4885CYP1A2 4302/4885CYP2D6 4339/4885 |
| US-11814384-B2 | Inhibtors of Raf kinases | RAF1, BRAF, ARAF | MAPT 3440/4885CYP1A2 4124/4885CYP2D6 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.